OSR Holdings, Inc. (OSRHW)
US Markets · Healthcare · Biotechnology
Closing price as of 2026-09-10 · Source: TEK2day Finance
About OSR Holdings, Inc.
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 628K | 381K | 484K | 316K |
| Gross Profit | 262K | 130K | 160K | 87K |
| Operating Income | (3.8M) | (6.4M) | (3.7M) | (3.0M) |
| Net Income | (2.1M) | (4.8M) | (2.9M) | (849K) |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3.5M | 2.9M |
| Gross Profit | 0.00 | 921K | 811K | 593K |
| Operating Income | (621K) | (1.8M) | (11.7M) | (18.3M) |
| Net Income | 1.1M | 404K | (10.3M) | (18.0M) |